Literature DB >> 28328109

Cohort study of Gorlin syndrome with emphasis on standardised phenotyping and quality of life assessment.

Aamira J Huq1, Michael Bogwitz1, Alexandra Gorelik2, Ingrid M Winship1,3, Susan M White4,5, Alison H Trainer1,3.   

Abstract

BACKGROUND: Gorlin syndrome (nevoid basal cell carcinoma syndrome) is a rare genetic predisposition to basal cell carcinomas (BCC), keratocysts of the jaw and calcification of the falx cerebri among other clinical features. With the advent of sonic hedgehog inhibitors for the treatment of BCC, it is timely to establish a cohort of individuals with Gorlin syndrome and collect standardised phenotypic information on these individuals. Moreover, the health-related quality of life (QoL) in individuals with Gorlin syndrome is not well studied. AIM: To establish a Victorian cohort of Gorlin syndrome and study the QoL in these individuals.
METHODS: Phenotypic data were obtained by reviewing medical records of individuals attending two major tertiary/quaternary genetic referral centres in Victoria, followed by telephone or face-to-face interviews where possible. QoL information was obtained utilising the AQoL-6D quality of life survey form.
RESULTS: The median number of BCC in the 19 individuals studied was 17.5 (interquartile range 3-70). The number of patients with ≥100 BCC in this group was similar to a previously described national cohort (22.2 vs 27% respectively). A total of 58% of referrals to the genetics clinics originated from maxillofacial surgeons and 42% from dermatologists. Individuals with ≥100 BCC had worse median QoL scores compared to those with <100 BCC (36 vs 29, P-value of 0.031).
CONCLUSION: The clinical features in our cohort were congruent with those previously described in Australia. The QoL is adversely correlated with increased BCC burden.
© 2017 Royal Australasian College of Physicians.

Entities:  

Keywords:  zzm321990zzm321990PTCH1zzm321990zzm321990; zzm321990zzm321990SUFUzzm321990zzm321990; Basal cell carcinoma (BCC); Gorlin syndrome; Gorlin-Goltz syndrome; basal cell nevus syndrome; nevoid basal cell carcinoma syndrome (NBCCS); quality of life in Gorlin syndrome

Mesh:

Year:  2017        PMID: 28328109     DOI: 10.1111/imj.13429

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  5 in total

1.  A guideline for the clinical management of basal cell naevus syndrome (Gorlin-Goltz syndrome).

Authors:  B J A Verkouteren; B Cosgun; M G H C Reinders; P A W K Kessler; R J Vermeulen; M Klaassens; S Lambrechts; J R van Rheenen; M van Geel; M Vreeburg; K Mosterd
Journal:  Br J Dermatol       Date:  2021-11-08       Impact factor: 11.113

2.  Cardiac Fibroma with Ventricular Tachycardia: An Unusual Clinical Presentation of Nevoid Basal Cell Carcinoma Syndrome.

Authors:  Alyssa L Ritter; Eric J Granquist; V Ramesh Iyer; Kosuke Izumi
Journal:  Mol Syndromol       Date:  2018-05-19

3.  Novel SUFU Frameshift Variant Leading to Meningioma in Three Generations in a Family with Gorlin Syndrome.

Authors:  Gustav Askaner; Ulrikke Lei; Birgitte Bertelsen; Alessandro Venzo; Karin Wadt
Journal:  Case Rep Genet       Date:  2019-07-28

4.  Proposed criteria for nevoid basal cell carcinoma syndrome in children assessed using statistical optimization.

Authors:  Nina B Gold; Ian M Campbell; Sarah E Sheppard; Wen-Hann Tan
Journal:  Sci Rep       Date:  2021-10-05       Impact factor: 4.379

5.  The relevance of a suppressor of fused (SUFU) mutation in the diagnosis and treatment of Gorlin syndrome.

Authors:  Taylor Ogden; Shauna Higgins; David Elbaum; Ashley Wysong
Journal:  JAAD Case Rep       Date:  2018-02-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.